Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria

The 8-aminoquinoline antimalarials, the only drugs which prevent relapse of vivax and ovale malaria (radical cure), cause dose-dependent oxidant haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients with

Saved in:
Bibliographic Details
Published in:PLoS neglected tropical diseases 2018-04, Vol.12 (4), p.e0006440-e0006440
Main Authors: Watson, James, Taylor, Walter R J, Bancone, Germana, Chu, Cindy S, Jittamala, Podjanee, White, Nicholas J
Format: Article
Language:English
Subjects:
Adolescent
Adult
Alleles
Aminoquinolines
Aminoquinolines - therapeutic use
Analysis
Antimalarial agents
Antimalarials - therapeutic use
Biology and Life Sciences
Blood
Causes of
Complications and side effects
Constrictions
Dehydrogenases
Dosage and administration
Drug dosages
Drug therapy
Drugs
Enzymatic activity
Enzyme activity
Enzymes
Female
Females
Frequency
Gene frequency
Glucosephosphate dehydrogenase
Glucosephosphate Dehydrogenase Deficiency - genetics
Haemolysis
Health aspects
Heterozygote
Human diseases
Humans
Infants
Lactation
Malaria
Malaria, Vivax - drug therapy
Male
Males
Medicine
Medicine and Health Sciences
Metabolism
Metabolites
Oxidizing agents
Patients
Phosphates
Plasmodium vivax
Plasmodium vivax - drug effects
Population genetics
Pregnancy
Prevention
Primaquine
Primaquine - therapeutic use
Tafenoquine
Tropical diseases
Vector-borne diseases
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The 8-aminoquinoline antimalarials, the only drugs which prevent relapse of vivax and ovale malaria (radical cure), cause dose-dependent oxidant haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients with
ISSN:1935-2735
1935-2727
1935-2735
DOI:10.1371/journal.pntd.0006440